Does 1 + Beat 2 +? And ADC-After-ADC

Category - Enhertu

How To Approach residual Disease After Neoadjuvant T-DXd

Managing T-DXd Toxicity: ILD Monitoring and the Curative Risk-Benefit Analysis in DB05

Adjuvant ADC Head-to-Head: DB05 Data Define a New Standard in Early HER2-Positive Breast Cancer

Deciphering the T-DXd Dilemma: Dual Success in DESTINY-Breast11 and DESTINY-Breast05

Safety Profile of Neoadjuvant T-DXd in DB11: Balancing ILD Risk Against Anthracycline Cardiotoxicity

T-DXd in the DB11 NACT Space: Is De-escalation in adjuvant setting Possible by Maximizing pCR?

The Predictive Power of 11%: Is T-DXd’s pCR Gain Enough for Long-Term Benefit?

DB11 and the Role of (T-DXd) in NACT high risk early stage HER2-Positive Breast Cancer

Dr. Mark Pegram and Dr. Neil Iyengar – T-DXd’s Rise in HER2+ & HER2-Low Breast Cancer

T-DXd and the CNS

PI3K? T-DXd Don’t Care

Can We Say “Cure”?